Trestolone Acetate (MENT)
MENT · Trest A
7α-methyl-19-nortestosterone acetate; potent, aromatizing, investigational male contraceptive.
Key takeaways
- Investigational 19-nor androgen developed for male contraception; never approved for any use.
- Acetate ester has a ~4-hour modeled half-life, so daily injection is the reported pattern.
- Aromatizes significantly to 7α-methylestradiol; estradiol management is central.
- Suppresses gonadotropins completely by design, so recovery planning is non-trivial.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Male contraception (clinical research) | 1–4 subdermal implants | Implant | Continuous release | Up to 12 months |
| Performance (community) | 10–50 mg | IM | Daily | 6–10 weeks |
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 3.7 hours
- Cmax
- 80.3 ng/dL
- Bioavailability
- 87%
- Typical dose
- 10–50 mg
Harm reduction
- Aromatizes
- Yes
- DHT derivative
- No
- Hepatotoxicity
- mild
- Injection frequency
- Daily
Frequently asked questions
Is trestolone the same as trenbolone?
No. Both are 19-nor androgens, but trestolone aromatizes heavily to a potent estrogen while trenbolone does not aromatize at all. Side-effect management on trestolone is closer to high-dose testosterone than to trenbolone.
Why daily injections?
The acetate ester clears with a roughly 4-hour modeled half-life, so levels fall off fast between doses. Less frequent injection produces large peaks and troughs; daily dosing is the community pattern for steadier levels.
Does trestolone shut down natural testosterone?
Completely and quickly, by design: it was developed to suppress gonadotropins for male contraception. Expect full HPTA suppression during use and plan recovery accordingly.
References
- Helsinki repository (MENT) — Cmax calibrated to ng/dL serum peak.
- Pharmacokinetics of MENT in men and monkeys (J Androl 1997) — Suvisaari et al.; the primary PK reference for trestolone.
- MENT implant suppression study (Hum Reprod 1999) — Gonadotropin and testosterone suppression in healthy men.
- Helsinki repository (MENT) — Entry's calibration source for the plotted curve.
Related compounds
Testosterone Enanthate
Long-acting testosterone ester; the most common TRT and cycle base. Reaches steady state in ~5 weeks.
Testosterone Cypionate
Standard US TRT ester with a slightly longer release tail than enanthate. Steady state ~4–5 weeks.
Testosterone Propionate
Short-acting ester with sharp peaks; requires frequent injection. Useful for frontloading.
Comments
Loading comments…